NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
59353-0004-10 | 59353-0004 | Epoetin alfa-epbx | RETACRIT | 4000.0 [iU]/mL, 4000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
59353-0010-10 | 59353-0010 | epoetin alfa-epbx | RETACRIT | 10000.0 [iU]/mL, 10000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
63629-1587-03 | 63629-1587 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 6, 2012 | In Use | |
31722-0775-60 | 31722-0775 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 19, 2024 | In Use | |
70377-0050-13 | 70377-0050 | Lenalidomide | Lenalidomide | 5.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
16714-0120-01 | 16714-0120 | Fosaprepitant | Fosaprepitant | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan 16, 2020 | In Use | |
72189-0183-90 | 72189-0183 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Feb 24, 2021 | In Use | ||
73207-0302-41 | 73207-0302 | Vimseltinib | ROMVIMZA | 14.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
00143-9217-01 | 00143-9217 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 30, 2017 | In Use | |
68788-7692-04 | 68788-7692 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 1, 2020 | In Use | |
57664-0024-97 | 57664-0024 | Isotretinoin | Isotretinoin | 35.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Dec 29, 2020 | In Use | |
73207-0304-41 | 73207-0304 | Vimseltinib | ROMVIMZA | 30.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R | Oral | Feb 14, 2025 | In Use | |
68071-3729-09 | 68071-3729 | PREDNISONE | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 14, 2025 | In Use | |
00555-0899-02 | 00555-0899 | Estradiol | Estradiol | 0.5 mg/1 | Hormonal Therapy | Estrogen | Oral | Oct 28, 1997 | In Use | ||
71205-0741-60 | 71205-0741 | PREDNISONE | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 6, 2023 | In Use | |
51655-0008-20 | 51655-0008 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 31, 2022 | In Use | |
00143-9517-01 | 00143-9517 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-Arterial, Intramuscular, Intrathecal, Intravenous | Jan 5, 2018 | In Use | |
42291-0321-01 | 42291-0321 | Hydroxyurea | Hydroxyurea | 500.0 mg/1 | Chemotherapy | Miscellaneous Agent | Antimetabolite/Organooxygen | Oral | Jul 23, 2013 | In Use | |
70377-0049-12 | 70377-0049 | Lenalidomide | Lenalidomide | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 3, 2025 | In Use | |
71335-2396-01 | 71335-2396 | Letrozole Tablets | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Apr 19, 2024 | In Use | ||
55111-0172-30 | 55111-0172 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 28, 2007 | In Use | |
72603-0189-01 | 72603-0189 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 7, 2023 | In Use | |
17856-0815-02 | 17856-0815 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 15, 2025 | In Use | |
55513-0057-01 | 55513-0057 | Darbepoetin alfa | Aranesp | 25.0 ug/.42mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use | ||
57962-0140-12 | 57962-0140 | Ibrutinib | Imbruvica | 140.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Nov 13, 2013 | In Use |
Found 11564 results — Export these results